Zelira Therapeutics Limited announce a collaboration with the Parkinson's Foundation, to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies. In 2019, Zelira Therapeutics participated in the Medical Cannabis Conference organized by the Parkinson's Foundation, and is now assisting in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD. This collaboration combines the Foundation's understanding of the underlying science of Parkinson's disease and the most prevalent symptoms impacting people with the disease with Zelira Therapeutics' extensive experience in pharmaceutical and condition-specific medical cannabis product development. As part of this collaboration, Zelira and Parkinson's Foundation will: Consult on the development of a survey tool to be sent to people with Parkinson's to understand why and how they are using medical cannabis and hemp-derived CBD products currently; review the results as they relate to a future clinical trial on the safety and efficacy of medical cannabis use by people with Parkinson's disease. Separately, Zelira will: Incorporate survey insights to inform future development of clinically validated medical cannabis and hemp-derived CBD medicines for people with Parkinson's disease, and provide guidance to people with Parkinson's regarding various cannabinoid-based and hemp-derived CBD treatment alternatives.